Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Biden to supply Kyiv with long-range ATACMS missiles after months of lobbying
    • The decoy weapons leading Russian forces astray in Ukraine
    • US government heads for shutdown as Republicans squabble over spending
    • Russian state TV promotes new Tucker Carlson show
    • US senator Robert Menendez indicted on federal bribery charges
  • UK
    Sections
    • UK Home
    • UK Economy
    • UK Politics
    • Brexit
    • UK Companies
    • Personal Finance
    Most Read
    • Jeremy Hunt plans Isa overhaul to boost share ownership
    • Conservatives auction dinner with UK chancellor and golf with David Cameron
    • Rishi Sunak considers move to ban smoking for next generation
    • Why Rishi Sunak thinks his net zero gamble will revive Tory prospects
    • What Rishi Sunak’s net zero overhaul means for UK emissions
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • UK press slams axing of Facebook News as ‘urgent threat to democracy’
    • Crispin Odey faces first lawsuit over alleged sexual misconduct
    • US auto strike expands to 38 General Motors and Stellantis facilities
    • Daniel Křetínský sells Le Monde stake to Xavier Niel
    • Auto industry recovery has favoured investors and bosses over workers
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • Jeremy Hunt plans Isa overhaul to boost share ownership
    • The risks of money-market funds need careful watching
    • Investors devour risky corporate debt in boost to LBO business
    • US dollar hits six-month high as markets accept new interest rate regime
    • Russia plans to increase spending by more than 25% next year
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Russell Brand learnt his tricks in television studios
    • Populism could derail the green transition
    • Britain should lead in life sciences but NHS inertia is holding it back
    • How to save your state pension
    • Starmer needs to untangle Labour’s intentions on Europe
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • ‘There is no work to balance’: how shrinking budgets, Covid and AI shook up life in consulting
    • American Express’s Steve Squeri: ‘If you’re not ready for the upswing, you’ve missed’
    • FT Business Books — what to read this month
    • Can I start a business when I have MS?
    • The plight of the hidden carers in your workforce
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Raffles London and the new era of super-luxe hospitality
    • Anna Wintour: ‘I just have to make sure things are being done right’
    • What is it about men and the Roman empire?
    • Who’d invite the boss to dinner?
    • Winners don’t do irony
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Sanofi SA

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Monday, 1 May, 2023
    Lex
    Sanofi/Provention: innovative diabetes drug is a good fit Premium content

    French pharma group needs new assets after trial failure of cancer treatment amcenestrant

    The Sanofi headquarters in France
  • Friday, 3 February, 2023
    UK at risk of losing healthcare innovation race with rivals, warns Sanofi boss

    Chief executive Paul Hudson sounds the alarm over British government’s cuts to research

    Paul Hudson
  • Tuesday, 6 December, 2022
    Pharmaceuticals sector
    GSK and Sanofi shares surge after Zantac ruling victory

    US judge dismisses almost 2,500 lawsuits alleging links between heartburn medication and cancer

    Zantac heartburn pills
  • Monday, 5 September, 2022
    Sanofi nominates SocGen boss Frédéric Oudéa as chair

    Change comes as French pharma group pours money into immunology and cancer research

    Société Générale chief executive Frédéric Oudéa
  • Wednesday, 17 August, 2022
    Sanofi drops experimental breast cancer drug after second trial fails

    Shares in French pharma group tumble nearly 6% after blow to pipeline of new treatments

    Sanofi logo
  • Thursday, 11 August, 2022
    Pharmaceuticals sector
    Pharma groups lose £30bn of value on heartburn drug lawsuit worries

    Companies face thousands of pending personal injury cases linking Zantac to cancer

    A box of Zantac tablets on a pharmacy shelf
  • Friday, 24 June, 2022
    Covid-19 vaccines
    Sanofi-GSK Covid vaccine found effective against Omicron

    Pharma companies are hoping to catch up with rivals as they report promising trial results for jab

    A vial labelled Sanofi and GSK Covid-19 vaccine
  • Monday, 13 June, 2022
    Sanofi and GSK report ‘positive’ results from Covid booster

    ‘Next-generation’ jab delivers strong immune response against variants

    A Sanofi logo next to a syringe and a Covid-19 vaccine vial
  • Tuesday, 17 May, 2022
    Electric vehicles
    Unilever and Sanofi pile on pressure over 2035 EU petrol ban

    Cross-section of companies want to ‘ensure laggards don’t delay the market shift’

    An Uber driver charges his Nissan Leaf electric vehicle at a Belib charging station at the Petit Palais in Paris, France, on April 13 2022
  • Wednesday, 23 February, 2022
    Covid-19 vaccines
    Sanofi and GSK to seek approval for delayed Covid vaccine

    Drugmakers to apply for protein-based shot to be used as primary and booster jabs

    A woman wearing a facemask walks past the Sanofi headquarters
  • Friday, 4 February, 2022
    Sanofi buoyed by blockbuster eczema drug Dupixent

    French pharma group still working on long-delayed Covid vaccine

  • Wednesday, 15 December, 2021
    Sanofi pushes back expected Covid vaccine approval date again

    French pharma group says jab will probably come to market in first quarter of 2022

  • Tuesday, 28 September, 2021
    Covid-19 vaccines
    Sanofi stops development of Covid vaccine based on mRNA technology

    French group says it is too late to market jab and is working on another with GSK using different technique

    A Sanofi logo and a Covid-19 vaccine bottle
  • Tuesday, 3 August, 2021
    Lex
    Sanofi/Translate Bio: do recruit the messenger Premium content

    The acquisition is a sign of the French pharma group’s determination to get back on the podium

    Sanofi headquarters in Paris
  • Tuesday, 3 August, 2021
    Sanofi to buy partner Translate Bio for $3.2bn in mRNA push

    French pharma group tries to catch up with rivals that used the technology to create Covid vaccines

    The Sanofi headquarters in Paris
  • Thursday, 29 July, 2021
    Sanofi raises annual profit goal

    French group still aims for its Covid-19 jab to be approved by year end

    Sanofi’s headquarters in Paris
  • Wednesday, 28 July, 2021
    Coronavirus
    Coronavirus: Biden reveals mandates and calls for incentives to boost vaccinations - as it happened
  • Tuesday, 29 June, 2021
    Sanofi boosts investment in mRNA to keep pace in vaccines

    French group to open a ‘dedicated mRNA centre of excellence’ after falling behind in Covid-19 jab race

    Sanofi campus in the Gentilly district in Paris, France
  • Tuesday, 15 June, 2021
    Sanofi agrees to inject tens of millions of pounds into UK pension scheme

    Britain’s pension regulator says French drugmaker began talks after threat of enforcement action

    Sanofi logo outside one of the company’s buildings in Paris
  • Monday, 17 May, 2021
    Covid-19 vaccines
    GSK seeks to make up ground in vaccine race

    UK group and France’s Sanofi release trial data of Covid jab showing strong immune response

    GSK’s manufacturing facility in Wavre, Belgium
  • Friday, 12 March, 2021
    Covid-19 vaccines
    Sanofi to start human trials of mRNA vaccine against Covid-19

    French group has fallen behind newcomers despite being one of the biggest jab makers in world

  • Wednesday, 10 March, 2021
    News in-depthFT Film24 min
    Covid-19 and the business of vaccines

    New vaccine producers and mRNA technology are shaking up the market

  • Tuesday, 16 February, 2021
    News in-depthCovid-19 vaccines
    Why the three biggest vaccine makers failed on Covid-19

    GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology

  • Friday, 5 February, 2021
    European companies
    Sanofi to expand cost-savings push to bolster R&D efforts

    French vaccine maker aims to get a Covid-19 shot to market by the fourth quarter

  • Monday, 11 January, 2021
    Lex
    Sanofi/Kymab: reliance on science Premium content

    Deal is latest in string of acquisitions that have given drugmaker access to new technologies

    A lab technician at Sanofi’s plant near Paris
Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

UK Edition

Subscribe for full access
  • Switch to International Edition

Top sections

  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • UK
    • UK Economy
    • UK Politics
    • Brexit
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • Today’s Newspaper (FT Digital Edition)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In